Teladoc Health news

Stock underperformed the broader market with a 2.38% daily decline and 7.1% monthly loss. Projected earnings are negative at -$0.23 per share with a 9.52% year-over-year decline. Quarterly revenue is expected to decline 6.53% year-over-year. Recent analyst estimate revisions have decreased by 1.62%, indicating weakening confidence. The stock carries a neutral Zacks Rank of #3 (Hold).

Stock declined 3.46% significantly outpacing market losses. Projected earnings are negative (-$0.23 EPS) with a 9.52% YoY decline. Revenue is expected to decrease 6.53% YoY. Consensus EPS estimates have declined 1.78% in the last 30 days. The company holds a neutral Zacks Rank #3 (Hold) rating, indicating lack of analyst confidence.

Stock declined 2.33% while market rose, with projected earnings per share down 9.52% YoY and revenue down 6.53% YoY. EPS estimates have been revised lower by 1.28% in the past 30 days. The company holds a Zacks Rank #3 (Hold) rating, indicating lack of positive momentum.

Mixed outlook with positive growth drivers (chronic care enrollment up 14% YoY, international revenue growth, Teladoc One platform launch) offset by significant concerns including BetterHelp revenue decline of 11.6%, razor-thin EBITDA margins at 0.2%, intense competition, and continued unprofitability. Zacks Rank #3 (Hold) reflects this balanced risk-reward profile.

Company issued significant revenue guidance downgrade (down ~5.6% at midpoint), reported operational challenges with BetterHelp platform including accelerated cash pay decline and network capacity issues, and faced a severe 38.32% stock price drop following the announcement. Additionally, the company is now subject to a securities fraud investigation.

The company is launching an innovative, comprehensive care model that addresses major healthcare challenges (fragmentation, rising costs). The outcome-based payment structure demonstrates confidence in the model's effectiveness. Strong partnerships (NBA Players Association, Walmart, Instacart) and high client retention (67% with multiple products) indicate market validation and growth potential.

The article reports a routine employment inducement award for a new executive hire. While this indicates company growth and hiring activity, it is a standard corporate action without material financial or operational impact disclosed. The news is informational rather than indicating positive or negative developments.

Complete insider divestment signals lack of confidence. The company has declined 72% over three years (CAGR -34.5%), significantly underperforming the S&P 500. Despite beating revenue expectations, Teladoc posted a $171 million net loss over the trailing twelve months and continues to struggle with profitability during a business model transition.

Listed as one of the undervalued healthcare stocks mentioned in the article. The Motley Fool has positions in and recommends the stock.

Company's BetterHelp platform reported 10 million monthly therapy sessions in 2025, demonstrating significant scale and market leadership in the rapidly growing telepsychiatry sector.

Plummeted over 26.8% on a guidance cut.

Listed as a leading player in the telehealth services segment, which is identified as the fastest-growing segment globally during the 2026-2035 forecast period.

Company faces significant competitive pressures, stalled visit growth, declining BetterHelp memberships, persistent unprofitability, and limited success with international expansion and third-party coverage efforts. Author explicitly recommends staying away from the stock.

Actively acquiring and expanding its digital mental health portfolio through the BetterHelp acquisition, positioning itself as a consolidator in the growing telehealth market.